Clinical Trial: Jaktinib for Steroid-Refractory Acute Graft-Versus-Host Disease

U.S., Oct. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07885228) titled 'Jaktinib for Steroid-Refractory Acute Graft-Versus-Host Disease' on Oct. 13.

Brief Summary: Graft-versus-host disease (GVHD) is a common severe complication and a primary cause of mortality following allogeneic hematopoietic stem cell transplantation (allo-HSCT).Previous studies have demonstrated that the JAK/STAT signaling pathway exerts anti-GVHD effects by reducing the expression of pro-inflammatory cytokines, thereby inhibiting T-cell signaling transduction. Jaktinib is a broad-spectrum kinase inhibitor that targets non-receptor tyrosine Janus-associated kinases (JAK1, JAK2, JAK3, and TYK2), as well as FLT3 (FMS-like tyrosine ki...